Nrf2 activator-23
Nrf2 activator-23 is an orally active Keap1 binder and Nrf2 activator, with KD values of 28.68 nM and 54.55 nM for Keap1 and its Kelch domain, respectively. Nrf2 activator-23 disrupts the Keap1-Nrf2 interaction, reduces ubiquitination and degradation of Nrf2, and activates the Nrf2 signaling pathway. Nrf2 activator-23 inhibits RANKL-induced osteoclast formation, bone resorptive activity, ROS production, and activation of the MAPK and NF-κB signaling pathways, while downregulating the expression of osteoclast-specific genes and proteins. Nrf2 activator-23 attenuates bone loss and reduces osteoclast formation in vivo without affecting osteoblast differentiation and mineralization. Nrf2 activator-23 can be used for the research of osteoporosis.
For research use only. We do not sell to patients.
- CAS No.: 3109883-60-2
- Formula: C23H17FO2Se
- Molecular Weight:423.34
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Nrf2 activator-23 (compound 5c) (1 μM; 4-7 d) inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells, with an IC50 of 0.499 μM after 7 days of treatment[1].
Nrf2 activator-23 (0.5-2 μM; 7 d) dose-dependently disrupts the formation of F-actin rings, reduces osteoclast volume, and decreases the number of nuclei per osteoclast in RANKL-stimulated bone marrow macrophages (BMMs) after 7 days of treatment[1].
Nrf2 activator-23 (0.5-2 μM; 7 d) inhibits RANKL-stimulated bone resorption by BMMs in a dose-dependent manner, and achieves nearly complete inhibition at the concentration of 2 μM after 7 days of treatment[1].
Nrf2 activator-23 (0.5-2 μM; 7 d) dose-dependently downregulates the mRNA expression levels of key genes (C-Fos, MMP-9, TRAP, NFATc1, CTSK, DC-STAMP) associated with osteoclast differentiation and function in RANKL-stimulated BMMs[1].
Nrf2 activator-23 (0.5-2 μM; 4 d) dose-dependently downregulates the protein expression of key markers for osteoclast differentiation and function (NFATc1, MMP-9, C-Fos, CTSK) in RANKL-stimulated bone marrow-derived macrophages (BMMs)[1].
Nrf2 activator-23 (0.5-2 μM; 48 h) inhibits RANKL-induced intracellular and mitochondrial ROS production in bone marrow macrophages (BMMs) in a dose-dependent manner, with a treatment duration of 48 h[1].
Nrf2 activator-23 (1 μM; 48 h) reduces the ubiquitination level of Nrf2 in BMMs and inhibits its proteasomal degradation[1].
Nrf2 activator-23 (1 μM; 6 h) inhibits the activation of MAPK (p38, ERK, JNK) and NF-κB (p65, IκBα) signaling pathways in RANKL-induced BMMs after 6 h of pretreatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RANKL-induced mouse bone marrow macrophages (BMMs)
-
Concentration:0.5-2 μM
-
Incubation Time:~7 days (until osteoclast formation)
-
Result:Dose-dependently reduced the mRNA expression of all tested osteoclast-specific genes.
Reduced C-Fos, MMP-9, TRAP, NFATc1, and CTSK expression to <20% of the RANKL-induced control, and DC-STAMP expression to ~30% of the control at 2 μM.
-
Cell Line:RANKL-induced mouse bone marrow macrophages (BMMs)
-
Concentration:0.5-2 μM
-
Incubation Time:4 days
-
Result:Dose-dependently reduced the protein expression of NFATc1, MMP-9, C-Fos, and CTSK compared to the RANKL-induced control.
Reduced NFATc1 and C-Fos expression to <50% of the control, and MMP-9 and CTSK expression to ~40% of the control at 2 μM.
-
Cell Line:RANKL-induced mouse bone marrow macrophages (BMMs)
-
Concentration:1 μM
-
Incubation Time:6 h pre-incubation, followed by RANKL stimulation for up to 60 min
-
Result:Attenuated RANKL-induced phosphorylation of p38, ERK, JNK, p65, and IκBα in a time-dependent manner.
Reduced p38, ERK, and JNK phosphorylation to ~60-70% of the control, and p65 and IκBα phosphorylation to ~50-60% of the control at 10 min post-RANKL stimulation.
Parmacokinetics
| Species | Dose | Route | AUC0-t | Cmax | T1/2 | Bioavailability |
|---|---|---|---|---|---|---|
| Mice[1] | 10 mg/kg | p.o. | 5069 ng·h/mL | 223 ng/mL | >24 h | 9.4 % |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (7-week-old female, ovariectomized)[1]
-
Dosage:10 mg/kg
-
Administration:p.o.; every other day; 8 weeks
-
Result:Increased bone volume/total bone volume (BV/TV), trabecular number (Tb.N), and trabecular thickness (Tb.Th), while decreasing trabecular spacing (Tb.Sp) compared to OVX controls.
Prevented the decrease in bone surface (BS) caused by ovariectomy.
Markedly reduced the increase in osteoclast surface/bone surface (Oc.S/BS) ratio induced by OVX.
Promoted gene expression of Nfe2l2 and Cat.
Showed no obvious toxicity, with no differences in body weight or organ histology (heart, liver, spleen, lung, kidney).
Chemical Information
-
CAS No. 3109883-60-2
-
Molecular Weight 423.34
-
Formula C23H17FO2Se
-
SMILES
O=C1C=C(OC2=CC(F)=CC([Se]C3=CC(C)=CC=C3)=C21)C4=CC=CC(C)=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Mesenchymal stromal/stem cell osteogenic differentiation
Mesenchymal stromal/stem cells can be induced toward an osteoblast-like lineage in vitro by culture in osteogenic medium containing dexamethasone, ascorbic acid or ascorbate-2-phosphate, and β-glycerophosphate; the differentiation process is commonly evaluated by alkaline phosphatase activity, osteogenic marker expression, collagenous matrix formation, and calcium-rich matrix mineralization. The main readouts are alkaline phosphatase activity as an early osteogenic marker and Alizarin Red S staining as a calcium-deposit readout for mineralized extracellular matrix; Alizarin Red S can be inspected microscopically or extracted and measured colorimetrically at 405 nm.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Osteoclast differentiation from monocyte/macrophage precursors
Osteoclast differentiation is an in vitro induction assay in which monocyte/macrophage-lineage precursors are exposed to macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL), generating multinucleated osteoclasts that are commonly identified by tartrate-resistant acid phosphatase (TRAP) staining and functionally confirmed by resorption pits on dentin, bone, or mineralized substrates. M-CSF supports survival and expansion of osteoclast precursors, while RANKL binding to RANK drives osteoclast commitment, fusion, maturation, and resorptive function; osteoprotegerin inhibits this pathway by binding RANKL and preventing RANK activation. The main readouts are the number of TRAP-positive multinucleated cells, formation of F-actin rings, and resorbed surface area; TRAP-positive multinucleated cells indicate osteoclast differentiation, whereas pit formation on dentin, bone, or mineralized coating indicates functional bone-resorbing activity.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)